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Background: The choice of cardiac resynchronization therapy device, with (CRT-D) or without (CRT-P) a deﬁ-
brillator, in patients with heart failure largely depends on the physician's discretion, because it has not been
established which subjects beneﬁt most from a deﬁbrillator.
Methods: We examined the annual trend of CRT device implantations between 2006 and 2014, and evaluated
the factors related to the device selection (CRT-D or CRT-P) for primary prevention of sudden cardiac death in
patients with heart failure by analyzing the Japan Cardiac Device Treatment Registry (JCDTR) database from
January 2011 and August 2015 (CRT-D, n¼2714; CRT-P, n¼555).
Results: The proportion of CRT-D implantations for primary prevention among all the CRT-D recipients was
more than 70% during the study period. The number of CRT-D implantations for primary prevention reached a
maximum in 2011 and decreased gradually between 2011 and 2014, whereas CRT-P implantations increased
year by year until 2011 and remained unchanged in recent years. Multivariate analysis identiﬁed age (odds ratio
[OR] 0.92, 95% conﬁdence interval [CI] 0.90–0.95, Po0.0001), male sex (OR 1.99, 95% CI 1.28–3.11, Po0.005),
reduced left ventricular ejection fraction (LVEF) (OR 0.96, 95% CI 0.94–0.98, Po0.0001), and non-sustained
ventricular tachycardia (NSVT) (OR 2.85, 95% CI 1.87–4.35, Po0.0001) as independent factors favoring the
choice of CRT-D.
Conclusions: Younger age, male sex, reduced LVEF, and a history of NSVT were independently associated with
the choice of CRT-D for primary prevention of sudden cardiac death in patients with heart failure in Japan.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiac resynchronization therapy (CRT) is an effective option
for the treatment of moderate to severe heart failure [1–6]. The
COMPANION trial [2] found that CRT with a deﬁbrillator (CRT-D)
was superior to that with a pacemaker (CRT-P) in terms of survivalblished by Elsevier B.V. This is an
: þ81 11 706 7874.
okoshiki).rate. However, direct comparisons of the efﬁcacy of these devices
are limited [2,7,8]. In fact, treatment with CRT-P also reduced all-
cause mortality during a longer follow-up period [3]. In addition,
the populations in these prospective studies consisted of patients
with less advanced age (average 67 years) [2,3], which may not
always represent our daily medical practice.
The major role of an implantable cardioverter-deﬁbrillator
(ICD) is to prevent sudden cardiac death due to ventricular
tachycardia (VT) or ﬁbrillation (VF). The MERIT-HF study reportedopen access article under the CC BY-NC-ND license
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class II–III was approximately 60%, whereas it was approximately
30% in patients with NYHA class IV [9]. A sub-analysis of the
COMPANION trial concluded that CRT-P and CRT-D both had
beneﬁcial effects on mortality and morbidity in the severely ill
population of NYHA class IV patients [10]. Moreover, the risk of
sudden cardiac death decreased in association with aging,
according to the Amiodarone Trialists MetAnalysis (ATMA) data-
base of 6252 patients with structural heart disease [11]. The cur-
rent guidelines from the European Society of Cardiology have
proposed that the better candidates for CRT-D vs. CRT-P are
patients with (1) stable heart failure, NYHA class II, (2) life
expectancy more than 1 year, (3) ischemic heart disease, and
(4) no comorbidities [12]. Therefore, the choice between CRT-D
and CRT-P may largely depend on the physician's discretion,
especially in patients without documented VT/VF who require CRT
for primary prevention.
The present study aimed to examine national trends in the use
of CRT devices and to determine factors affecting the choice of
CRT-D in heart failure patients, based on data from the Japan
Cardiac Device Treatment Registry (JCDTR) [13–15].2. Materials and methods
2.1. Study population
The JCDTR was established in 2006 by the Japanese Heart
Rhythm Society (JHRS) for a survey of actual conditions in patients
undergoing implantation of cardiac implantable electronic devices
(ICD/CRT-D/CRT-P) [13–15]. Members of the JHRS are encouraged
to register their data under a uniﬁed protocol, which was normally
approved by each facility. In Hokkaido University Hospital, the
protocol was approved on September 20, 2012, by the Ethics
Committee (approval number: 012-0156). As of January 30, 2016,
367 facilities in Japan have registered data voluntarily. The annual
trend of implantation procedures was calculated from all the data
until the end of 2014, except for 494 procedures with unknown
devices. The comparative analyses between CRT-D and CRT-P for
primary prevention were performed using records from the JCDTR
database with an implantation date between January 2011 and
August 2015 (Fig. 1). In addition, the JCDTR database from January
2006 to August 2010 (Supplemental Fig. 1) was also analyzed to
determine whether there is a temporal trend regarding the choice
of CRT devices.Fig. 1. Study population enrolled for the comparative analysis of CRT-D and CRT-P
recipients for primary prevention during the period from January 2011 to August
2015. CRT, cardiac resynchronization therapy (¼biventricular pacing); CRT-D, CRT
with implantable cardioverter-deﬁbrillator; CRT-P, CRT pacemaker.2.2. Statistical analysis
All data are expressed as mean7SD. Simple between-group
analysis was conducted using Student's t-test. Categorical variables
were compared using Fisher's exact test. Logistic regression ana-
lysis was used to estimate the factors affecting the choice of CRT-D
vs. CRT-P. Differences with Po0.05 were considered signiﬁcant.
Statview version 5.0 for Windows (SAS Institute Inc., Cary, NC,
USA) was used for all statistical analyses.3. Results
3.1. Trends in the implantation procedures of CRT devices
Implantation of CRT-P and CRT-D devices started in April, 2004
and August, 2006, respectively, in Japan. The annual totals of
implantation procedures for CRT-D and CRT-P from the JCDTR
database are given in Fig. 2A. Among all the procedures (including
ICD), the percentage of CRT devices was constant at approximately
40% in recent years. The CRT-D implantation procedures were
divided into those used for primary and secondary prevention
(Fig. 2B). The number of CRT-D devices implanted for primary
prevention reached a maximum in 2011 and decreased gradually
between 2011 and 2014. In recent years, primary prevention
accounted for approximately 70% of all CRT-D implantations. In
contrast, the number of CRT-P implantations stayed almost con-
stant between 2011 and 2014 (Fig. 2A).Fig. 2. Annual distribution of cardiac implantable electronic device implantations
between 2006 and 2014 from the JCDTR database. (A) Distribution of CRT-D and
CRT-P implantations. The yellow line indicates the percentage of CRT devices (CRT-
D and CRT-P) among all the devices (including ICD/CRT-D/CRT-P). (B) Distribution
of CRT-P and CRT-D implantations for primary and secondary prevention. The
yellow line indicates the percentage of primary prevention among all the CRT-D
recipients. CRT, cardiac resynchronization therapy (¼biventricular pacing); CRT-D,
CRT with implantable cardioverter-deﬁbrillator; CRT-P, CRT pacemaker; ICD,
implantable cardioverter-deﬁbrillator.
Table 1
Patient characteristics.
CRT-D (n¼2714) CRT-P (n¼555 ) P-value
Age (years) 67.5710.9 74.7710.9 o0.0001
Male sex 2060 (75.9) 341 (61.4) o0.0001
Underlying heart disease 0.603
Ischemic 768 (28.3) 150 (27.0)
Non-ischemic 1946 (71.7) 405 (73.0)
LVEF (%) 27.479.3 32.5711.2 o0.0001
LVEFr35% 2385 (87.9) 392 (70.6) o0.0001
NYHA class 0.151
I 52 (1.9) 15 (2.7)
II 654 (24.1) 125 (22.5)
III 1722 (63.4) 370 (66.7)
IV 286 (10.5) 45 (8.1)
Heart rate (/min) 70.6716.9 69.6718.0 0.171
QRS duration (ms) 154.7730.1 161.2729.3 o0.0001
o120 ms 320 (11.8) 35 (6.3)
120–149 ms 790 (29.2) 138 (25.0)
Z150 ms 1595 (58.0) 380 (68.7)
QT interval (ms) 456.7753.7 468.1754.6 o0.0001
Atrial lead 0.0074
Absent 405 (14.9) 108 (19.5)
Present 2309 (85.1) 447 (80.5)
NSVTa 721 (69.7)a 48 (41.7)a o0.0001
AF 352 (13.0) 81 (14.6) 0.304
Type of AF 0.049
Paroxysmal/persistent 132 (38)/220 (62) 21 (26)/60 (74)
Diabetes mellitus 884 (32.6) 187 (33.7) 0.608
Hypertension 1132 (41.7) 281 (50.6) 0.0001
Dyslipidemia 880 (32.4) 161 (29.0) 0.116
Hyperuricemia 522 (19.2) 95 (17.1) 0.246
Cerebral infarction 183 (6.7) 42 (7.6) 0.484
Peripheral artery disease 91 (3.4) 27 (4.9) 0.082
BNP (pg/mL) 710.871143.2 766.27902.8 0.338
Hemoglobin (g/dL) 12.772.0 12.171.9 o0.0001
Creatinine (mg/dL) 1.4971.49 1.5271.51 0.6226
Values are mean7SD, or number (%).
NSVT, non-sustained ventricular tachycardia; AF, atrial ﬁbrillation.
a Information about the presence or absence of NSVT was available in 1034
CRT-D recipients and 115 CRT-P recipients.
Table 2
Pharmacological therapy.
CRT-D (n¼2714) CRT-P (n¼555) P-value
Ia 20 (0.74) 5 (0.90) 0.686
Ib 57 (2.10) 11 (1.98) 0.859
Ic 15 (0.55) 4 (0.72) 0.635
β-Blockers 2128 (78.4) 352 (63.4) o0.0001
III 871 (32.1) 88 (15.9) o0.0001
Ca2þ antagonists 226 (8.3) 69 (12.4) 0.0021
Digitalis 319 (11.8) 62 (11.2) 0.697
Diuretics 2106 (77.6) 418 (75.3) 0.243
ACEI/ARB 1813 (66.8) 333 (60.0) 0.0021
Aldosterone antagonists 1152 (42.4) 203 (36.6) 0.011
Nitrates 232 (8.5) 53 (9.6) 0.446
Statins 810 (29.8) 141 (25.4) 0.036
Oral anticoagulant agents 1332 (49.1) 246 (44.3) 0.041
Antiplatelet agents 992 (36.6) 193 (34.8) 0.428
Data are given as number (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blockers.
Fig. 3. Proportion of CRT devices registered in the JCDTR by non-university (A) and
university (B) hospitals. Among the study population (given in Fig. 1), 2160 patients
and 1109 patients were enrolled from non-university hospitals and university
hospitals, respectively. The proportion of CRT-P devices registered was 20.6% of
patients from non-university hospitals and 9.9% of patients from university hos-
pitals (Po0.0001). Conversely, the proportion of patients who had a CRT-D device
for primary prevention was 79.4% in non-university hospitals and 90.1% in uni-
versity hospitals.
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The characteristics of patients receiving CRT-D (n¼2714) and
CRT-P (n¼555) devices for primary prevention are shown in Table 1.
Among 2714 CRT-D recipients, 2620 underwent initial implantation,
whereas 35 and 59 patients were upgrades from CRT-P and ICD,
respectively. Age, left ventricular ejection fraction (LVEF), QRS dura-
tion, and QT interval were signiﬁcantly lower in patients with CRT-D
than in those with CRT-P. Male sex was prevalent in both groups, but
its predominance was higher in patients with CRT-D. Patients
receiving CRT-D were more likely to have a history of non-sustained
ventricular tachycardia (NSVT). In contrast, they were less likely to
have a history of persistent atrial ﬁbrillation (AF) or hypertension.
The percentage receiving a CRT device without an atrial lead was
lower in CRT-D patients. The distributions of NYHA functional class
and underlying heart diseases (ischemic vs. non-ischemic) were
similar between the groups.
Pharmacological therapy in patients receiving CRT-D or CRT-P is
shown in Table 2. Use of β-blockers, class III antiarrhythmic drugs,
angiotensin-converting enzyme inhibitors or angiotensin II receptor
blockers, aldosterone antagonists, statins, and oral anticoagulant
agents was signiﬁcantly higher in patients receiving CRT-D. Ca2þ
antagonists were prescribed in a lower percentage of patients with
CRT-D.
The type of hospital affected the choice of CRT-P. As expected,
the proportion of CRT-P devices was higher in non-university
hospitals compared to university hospitals (Fig. 3, Po0.0001).
Conversely, the proportion of patients who had CRT-D for primaryprevention was higher in university hospitals. On the other hand,
β-blockers were given to 77.9% of CRT-D (n¼1715) and 62.7% of
CRT-P (n¼445) recipients in non-university hospitals (Po0.0001),
compared to 79.3% of CRT-D (n¼999) and 66.4% of CRT-P (n¼110)
recipients in University hospitals. Thus, the use of β-blockers did
not differ between non-university and university hospitals
(P¼0.400).
3.3. Factors affecting the choice of CRT-D for primary prevention
To evaluate the independent variables associated with CRT-D
(vs. CRT-P) implantation for primary prevention, logistic regres-
sion analysis, incorporating the demographic and comorbidity
data given in Table 1, was performed for the study population
between January 2011 and August 2015 (Fig. 1). In the multivariate
analysis, age (odds ratio [OR] 0.92, 95% conﬁdence interval [CI]
0.90–0.95, Po0.0001), male sex (OR 1.99, 95% CI 1.28–3.11,
Po0.005), LVEF (OR 0.96, 95% CI 0.94–0.98, Po0.0001), and the
presence of NSVT (OR 2.85, 95% CI 1.87–4.35, Po0.0001) were
signiﬁcant factors favoring the choice of CRT-D.
Patient characteristics from the database between January 2006
and August 2010 are summarized in Supplemental Table 1. Compared
to those from the recent database (Table 1), apparent differences were
observed in the age of those receiving CRT-P and a history of NSVT.
The age increased from 71.8711.7 to 74.7710.9 (P¼0.0080) in
patients with CRT-P, whereas it did not change in those with CRT-D
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with a history of NSVT decreased from 75.7% to 69.7% (Po0.0001).4. Discussion
In the present study, we examined data from the JCDTR database
that had been registered by the members of the JHRS from 2006 to
2014. We demonstrated that the number of CRT-D recipients for
primary prevention decreased after 2011, whereas the CRT-P
implants in recent years (i.e., between 2011 and 2014) remained
almost constant and were more numerous than in the preceding
years (i.e., between 2006 and 2010). In addition, we identiﬁed the
following independent factors for the choice of CRT-D in recent
years: younger age, male sex, lower LVEF, and a history of NSVT.
A subanalysis of the MADIT-CRT trial demonstrated that the
factors associated with an LVEF improvement (LVEF450%) by CRT
were female sex, no previous myocardial infarction, left bundle
branch block, baseline LVEF 430%, left ventricular end-systolic
volume r170 mL, and left atrial volume index r45 mL/m2 [16].
The patients with LVEF improvement had a low risk of VT/VF
(approximately 3% at 2 years) and a favorable clinical course
within 2.2 years of follow-up. QRS duration Z150 ms was also
associated with a reduction in echocardiographic left ventricular
end-diastolic volume in response to CRT-D [17]. A recent meta-
analysis demonstrated that male sex and ischemic heart disease
were signiﬁcant moderator variables for a stronger beneﬁt of CRT-
D vs. CRT-P in primary prevention recipients [18]. Taken together,
male patients with ischemic heart disease, lower LVEF, and less
prolonged QRS are less likely to show a good response to CRT,
thereby requiring ICD backup for primary prevention. In addition,
detection of NSVT (at least 18 beats in duration and at least
188 beats/min) indicated a 4.3-fold increase in the risk of appro-
priate ICD shocks in the heart failure patients enrolled for SCD-
HeFT [19]. Therefore, our tendency to select CRT-D would be rea-
sonable in terms of the identiﬁed factors such as male sex, lower
LVEF, and a history of NSVT. However, we should be cautious in the
interpretation of our results, because the present study did not
evaluate the patients’ outcomes.
A decreasing trend in CRT-D implantation has been reported
recently, based on the database from the National Inpatient Sam-
ple in the USA [20]. They found that advancing age and an
increasing comorbidity burden were associated with a reduced
likelihood of CRT-D, and speculated that the decline in CRT-D
implantation may reﬂect the intersection of high-comorbidity
patients and the expectation of reduced ICD beneﬁt in this
patient population [20]. We found some differences in the patient
characteristics between CRT-D and CRT-P (Table 1). These included
age, sex, LVEF, QRS duration, QT interval, hemoglobin, and history
of NSVT, hypertension, and persistent AF. However, when these
patients’ background data in recent years were compared to pre-
vious years, a signiﬁcant difference was observed only in age and
prior NSVT. Therefore, the decrease in CRT-D and the increase in
CRT-P implantation may be closely associated with the advancing
age of the population in recent years.
The proportion of CRT-D implantations in primary prevention
patients with a CRT device was 83% (2714 of 3269) in the present
study. This was comparable to the 86% found in the USA [20], and
was higher than the 69% reported in Europe (the CeRtiTuDe cohort
study) [21]. Differences in the patients’ characteristics between
CRT-D and CRT-P recipients were found by observational studies
from Japan (JCDTR), Europe [21], and the USA [20]. For example,
patients with AF were likely to receive CRT-P in Europe and the
USA; however, this was not apparent in Japan. The etiology of the
underlying heart diseases was one of the most striking differences.
In Japan, the prevalence of ischemic heart disease was less than30%, and it did not differ between the CRT-D and CRT-P popula-
tion. In contrast, the ischemic etiology was 49.3% of CRT-D and
40.7% of CRT-P (CRT-D vs. CRT-P, P¼0.003) in Europe [21], and
67.7% of CRT-D and 53.1% of CRT-P (CRT-D vs. CRT-P, Po0.001) in
the USA [20]. Because there appear to be some modulator vari-
ables inﬂuencing the beneﬁt of a deﬁbrillator in CRT patients [18],
differences in the choice of CRT devices and the patients’ back-
grounds could affect the clinical outcome of heart failure patients
requiring CRT. Further studies examining the prognosis of CRT
patients are necessary to validate our choice among CRT devices in
daily clinical practice in Japan.
4.1. Study limitations
This study had several limitations that need to be acknowl-
edged. First, the data entries in the JCDTR are not always con-
secutive and have been registered on a voluntary basis. However,
more than 367 facilities all over the country have contributed to
the registry, which thereby represents the trends in Japan. Second,
no information regarding QRS complex morphology was available
in the JCDTR database. Third, the prevalence of AF was relatively
low, despite the higher use of oral anticoagulants. This is probably
related to the data entry system of the JCDTR, which does not
require information regarding the presence or absence of AF in
order to ﬁnish the registration. Fourth, patients’ body mass index,
which could be a reason for selecting CRT-P, was not available from
the JCDTR database.5. Conclusions
CRT-D devices accounted for more than 80% of CRT implanta-
tions for primary prevention of sudden cardiac death in Japan.
However, the use of CRT-D has tended to decrease in recent years.
The independent factors favoring the choice of CRT-D in heart
failure patients without a history of sustained VT/VF were younger
age, male sex, reduced LVEF, and prior NSVT, based on the analysis
of the JCDTR database.Conﬂict of interest
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